Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hereditary Cancer in Clinical Practice
Published in: Hereditary Cancer in Clinical Practice 1/2015

Open Access 01-12-2015 | Letter to the Editor

PARP inhibitors

Authors: Maheen Anwar, Hafiz Muhammad Aslam, Shahzad Anwar

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2015

Login to get access

Abstract

Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anti-cancer drugs.
Literature
1.
2.
Amé JC, Spenlehauer C, de Murcia G: The PARP superfamily. Bioessays 2004,26(8):882–93. 10.1002/bies.20085CrossRefPubMed
3.
Hakmé A, Wong H-K, Dantzer F, Schreiber V: The expanding field of poly (ADP-ribosyl) ation reactions. EMBO Rep 2008,9(11):1094–100. 10.1038/embor.2008.191CrossRefPubMedPubMedCentral
4.
Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008;13:3046.CrossRefPubMed
5.
Schreiber V, Dantzer F, Ame JC, de Murcia G: Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006,7(7):517–28. 10.1038/nrm1963CrossRefPubMed
6.
Chang P, Jacobson MK, Mitchison TJ: Poly (ADP-ribose) is required for spindle assembly and structure. Nature 2004,432(7017):645–9. 10.1038/nature03061CrossRefPubMed
7.
Huber A, Bai P, Murcia JM, Murcia G: PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair 2004,3(8):1103–8. 10.1016/j.dnarep.2004.06.002CrossRefPubMed
8.
Chambon P, Weill J, Mandel P: Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 1963,11(1):39–43. 10.1016/0006-291X(63)90024-XCrossRefPubMed
9.
10.
Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramirez-Merino N: Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 2012,23(5):1156–64. 10.1093/annonc/mdr361CrossRefPubMed
11.
Luo X, Kraus WL: On PAR with PARP: cellular stress signaling through poly (ADP-ribose) and PARP-1. Genes Dev 2012,26(5):417–32. 10.1101/gad.183509.111CrossRefPubMedPubMedCentral
12.
Rowe BP, Glazer PM. Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res. 2010;12(2):203.
13.
McCabe N, Turner NC, Lord CJ, Kluzek K, Białkowska A, Swift S, Giavara S, O’Connor MJ, Tutt AN, Zdzienicka MZ: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 2006,66(16):8109–15. 10.1158/0008-5472.CAN-06-0140CrossRefPubMed
14.
Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A: Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009,1(6–7):315–22. 10.1002/emmm.200900041CrossRefPubMedPubMedCentral
15.
Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010,28(22):3555–61. 10.1200/JCO.2009.27.5719CrossRefPubMedPubMedCentral
16.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ: Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009,361(2):123–34. 10.1056/NEJMoa0900212CrossRefPubMed
17.
Bolderson E, Richard DJ, Zhou B-BS, Khanna KK: Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 2009,15(20):6314–20. 10.1158/1078-0432.CCR-09-0096CrossRefPubMed
18.
Munoz-Gamez J, Martín-Oliva D, Canuelo A, Nunez M, Ruiz dAJ, de Murcia G, Oliver F, Valenzuela M, Aguilar-Quesada R: PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 2005, 386: 119–25. 10.1042/BJ20040776CrossRefPubMedPubMedCentral
19.
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005,434(7035):913–7. 10.1038/nature03443CrossRefPubMed
20.
21.
Ferraris DV: Evolution of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 2010,53(12):4561–84. 10.1021/jm100012mCrossRefPubMed
22.
Kopetz S, Mita M, Mok I, Sankhala K, Moseley J, Sherman B, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol. 2008;26(15S):3577.
23.
Fong P, Boss D, Carden C, Roelvink M, De Greve J, Gourley C, et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J Clin Oncol. 2008;26(15S):Abstract 5510.
24.
25.
Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D: Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008,14(23):7917–23. 10.1158/1078-0432.CCR-08-1223CrossRefPubMedPubMedCentral
26.
Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, et al. First and final report of a phase II study of the poly (ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol. 2006;24(18S):8013.
27.
Sandhu S, Wenham R, Wilding G, McFadden M, Sun L, Toniatti C, et al. First-in-human trial of a poly (ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. J Clin Oncol (Meeting Abstracts). 2010;2010:3001.
28.
Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, Ator M, Husten J, Deibold J, Hudkins R: The selective poly (ADP-ribose) polymerase-1 (2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 2007,6(8):2290–302. 10.1158/1535-7163.MCT-07-0062CrossRefPubMed
29.
Russo AL, Kwon H-C, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ: In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009,15(2):607–12. 10.1158/1078-0432.CCR-08-2079CrossRefPubMed
30.
Masutani M, Nakagama H, Sugimura T: Poly-ADP-ribosylation in health and disease. Cell Mol Life Sci 2005,62(7–8):769–83. 10.1007/s00018-004-4509-xCrossRefPubMed
31.
Mota RA, Sánchez-Bueno F, Saenz L, Hernández-Espinosa D, Jimeno J, Tornel PL, Martínez-Torrano A, Ramírez P, Parrilla P, Yélamos J: Inhibition of poly (ADP-ribose) polymerase attenuates the severity of acute pancreatitis and associated lung injury. Lab Investig 2005,85(10):1250–62. 10.1038/labinvest.3700326CrossRefPubMed
32.
Pacher P, Szabó C: Role of poly (ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 2007,25(3):235–60. 10.1111/j.1527-3466.2007.00018.xCrossRefPubMedPubMedCentral
33.
Ford AL, Lee J-M. Climbing STAIRs towards clinical trials with a novel PARP-1 inhibitor for the treatment of ischemic stroke. Brain Res. 2011;1410:120.CrossRefPubMedPubMedCentral
34.
Underhill C, Toulmonde M, Bonnefoi H: A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011,22(2):268–79. 10.1093/annonc/mdq322CrossRefPubMed
Metadata
Title
PARP inhibitors
Authors
Maheen Anwar
Hafiz Muhammad Aslam
Shahzad Anwar
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2015
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-014-0024-8

Other articles of this Issue 1/2015

Hereditary Cancer in Clinical Practice 1/2015 Go to the issue

Research

The c.470 T > C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population

Case report

High-grade endometrial stromal sarcoma as the initial presentation of an adult patient with Peutz-Jeghers Syndrome: a case report

Research

Patient experiences living with pancreatic cancer risk

Research

Molecular diagnosis and comprehensive treatment of multiple endocrine neoplasia type 2 in Southeastern Chinese

Case report

A case of squamous cell carcinoma of the skin due to the molecularly confirmed Lynch Syndrome

Research

Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits